Expertise in
10
conditions

Dr. Stephen L. Richey

Texas Oncology PA
Fort Worth, TX
Expertise in
10
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
OverviewInsuranceLocationsClinical Research

Overview

Stephen Richey is a Hematologist Oncology specialist and an Oncologist in Fort Worth, Texas. Dr. Richey is highly rated in 10 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, Desmoplastic Small Round Cell Tumor, and Nephrectomy. Dr. Richey is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor Scott And White All Saints Medical Center
Texas Health Harris Methodist Hospital Fort Worth
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Moda Health
  •  Friday Health
  •  Scott and White Health
  •  UnitedHealthcare
View 2 More Insurances +

Locations

TEXAS ONCOLOGY PA
500 S Henderson St, Suite 200, Fort Worth, TX 76104
817-413-1500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 18, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: TP-0903
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Active_not_recruiting
Publish Date: September 13, 2023
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 21 Less Clinical Trials

11 Total Publications

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: July 09, 2019
Similar Doctors
Expertise in
30
conditions
Dr. Farrukh T. Awan
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Farrukh T. Awan
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (28.9 mi)
214-633-5555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Farrukh Awan is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Awan is highly rated in 30 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Awan is currently accepting new patients.

Expertise in
22
conditions
Dr. Larry D. Anderson
Oncology | Hematology | Hematology Oncology
Expertise in
22
conditions
Dr. Larry D. Anderson
Oncology | Hematology | Hematology Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (29.3 mi)
214-645-2700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Anderson is an Oncologist and a Hematologist in Dallas, Texas. Dr. Anderson is highly rated in 22 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Anderson is currently accepting new patients.

Expertise in
8
conditions
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology
Expertise in
8
conditions
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (29.3 mi)
214-645-0624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Brugarolas is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Brugarolas is highly rated in 8 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy. Dr. Brugarolas is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile